CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for IPI Legacy Liquidation Co is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

IPI Legacy Liquidation Co
201 ELLIOTT AVE. W, SUITE 260
Phone: (206) 568-1466p:206 568-1466 SEATTLE, WA  98119  United States Fax: (302) 674-5266f:302 674-5266
This company's Plan of Liquidation went into effect on 4/5/2024
This company ceased filing statements with the SEC on 3/26/2024.
This entity represents the bankrupt estate of the former businesses (assets) of Impel Pharmaceuticals Inc that were not sold to JN Bidco LLC on 2/12/2024
This company is no longer actively traded on any major stock exchange.
Business Summary
IPI Legacy Liquidation Co, formerly Impel Pharmaceuticals Inc., is not engaged in any business operations. The Company doesn’t hold any assets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-Founder, Chief Technology and Development Officer JohnHoekman 42 4/1/2021 7/1/2008
Chief Restructuring Officer BrandonSmith 12/18/2023 12/18/2023
Independent Director DavidAllison 41 6/1/2019 6/1/2019
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Impel NeuroPharma Australia Pty Ltd
Impel Neuropharma Australia Pty Ltd

General Information
Outstanding Shares: 23,900,031 (As of 11/8/2023)
Shareholders: 67
Stock Exchange: OTC
Federal Tax Id: 263058238
Fax Number: (302) 674-5266


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024